EffectiveNess of Low Dose Aspirin in GastrointEstinal Cancer Prevention - Taiwan
NCT ID: NCT03579732
Last Updated: 2020-09-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
4710504 participants
OBSERVATIONAL
2018-06-29
2019-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness of Low Dose Aspirin in Decreasing the Chance Getting Stomach and Intestine Cancer
NCT04081831
Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer
NCT00468910
Influence of Aspirin on Human Gut Microbiota Composition and Metabolome
NCT03450317
Assessment of Direct Biomarkers of Aspirin Action to Develop a Precision Chemoprevention Therapy of Colorectal Cancer
NCT03957902
The Colorectal Cancer Chemoprevention Acceleration and Improvement Platform (CRC-CHAMP) Study
NCT05402124
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Secondary objectives are to evaluate the protective effect by duration of low-dose aspirin use on colorectal cancer, the effect of discontinuation of aspirin on colorectal cancer prevention, the staging distribution of colorectal cancer and the description of fatal cases due to colorectal cancer.
Aspirin use will be identified through Taiwanese National Health Insurance (NIH) data from 2000 to 2015. Cancer cases and staging of the three cancer types will be ascertained through the Taiwan Cancer Registry, using data from 2000 to 2014. Fatal cases will be ascertained using Mortality database from 2000 to 2015.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Long-term users
Adults using low-dose aspirin for \> 3 years
Aspirin (Acetylsalicylic Acid, BAYE4465)
Low dose of aspirin, i.e. \< 150 mg daily
Episodic users
Adults using low-dose aspirin inconsistently, or consistently but \< 3 years
Aspirin (Acetylsalicylic Acid, BAYE4465)
Low dose of aspirin, i.e. \< 150 mg daily
Former users
Subset of adult Episodic users of aspirin who discontinued the drug for at least 1 year before case/ control date
Aspirin (Acetylsalicylic Acid, BAYE4465)
Low dose of aspirin, i.e. \< 150 mg daily
Non-consumers
Adults who did not use low-dose aspirin
No drug
Non-consumers
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aspirin (Acetylsalicylic Acid, BAYE4465)
Low dose of aspirin, i.e. \< 150 mg daily
No drug
Non-consumers
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Taiwanese National Health Insurance enrollees with non-missing and consistent age and gender information.
Exclusion Criteria
* No use of National Health Insurance before the cohort entry date.
* Low dose aspirin prescription before cohort entry date.
* Subjects with conditions contra-indicated for low dose aspirin use before cohort entry date.
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National University of Taiwan Hospital
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
19882
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.